Forbion
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
Mestag Therapeutics develops antibody treatments based on fibroblast immunology for cancer and inflammatory diseases. It is building therapies designed to direct and drive immune responses using fibroblast-immune biology.
Tropic secures £80m Series C led by Forbion and Corteva for gene-edited tropical crop varieties
Tropic develops gene-edited tropical crop varieties designed to improve disease resistance, shelf life and agricultural productivity. Its products aim to help growers, exporters and food supply chains manage crop disease, reduce waste and increase yields.
PACT secures £15m Series A led by Forbion and HV Capital to scale sustainable collagen-based material
PACT develops collagen-based biomaterials that replace plastic-coated textiles, supplying scalable, supple materials for fashion, interiors and automotive applications using surplus biological inputs.
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug
CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.
Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies
Verdiva Bio develops next-generation obesity and metabolic disease therapies, advancing oral and injectable treatment candidates to improve access, adherence and long-term outcomes.
More venture news
- 29 Jul 2026
LemonEdgeLemonEdge announced £16m Series A round led by Blackstone Innovations Investments for a fund accounting platform built for private markets
Series AFintech - 21 Jul 2026
HumanoidHumanoid unlocks £114m Series A led by Prime Movers Lab to deploy humanoid robots across industrial manufacturing and logistics
Series AIndustrial - 22 Jul 2026
ArrakisArrakis raises a £22m Series A led by Blossom Capital to install AI agents into industrial companies' mission-critical operations
Series AIndustrial
